The other problem with Biogen is the price point for a regimen. Way too expensive for the health care system.
AEMD's problem is its long history of trying to garner attention from the medical field with their limited financial resources. With their challenges over the years, there was rising short interest. The sharp spike in reaction to their news was partially due to short covering and the decline is reestablishing those short positions a higher prices.
Investors in biotechs have a tendency to suffer from ADD. Patience is not their forte.
News 
Market Data 
Discover 
